In this study, an at least 30-fold margin between hERG’s half maximal inhibitory concentration (IC50; indicates the quantity of substance needed to inhibit a given biological process in vitro by 50%) and the maximal concentration after 1 dose of cannabidiol (Cmax) has been proposed to be an acceptable degree of safety from arrhythmogenesis.5 There are human pharmacokinetic data showing that the Cmax values for CBD can reach 0.35–0.58 μM after smoking (19.2 mg) and oral intake (400 mg), respectively.6 Based on Orvos and colleagues,5 who showed that CBD had an inhibitory effect on hERG channel activity with an IC50 value of 2.07 μM, the ingestion of 400 mg of CBD results in a ratio of 3.57 (<30), thus suggesting the potential of proarrhythmic side effects in humans, especially in case of interactions with the metabolism of CBD.6 In vitro, CBD inhibits CYP isozymes (mainly CYP3A4 and CYP2C19),7 but it is unclear whether this occurs at concentrations achieved with doses used clinically.

There is created in the State treasury a special fund, which shall be held separate and apart from all other State moneys, to be known as the Cannabis Business Development Fund. The Cannabis Business Development Fund shall be exclusively used for the following purposes:        (1) to provide low-interest rate loans to Qualified      Social Equity Applicants to pay for ordinary and necessary expenses to start and operate a cannabis business establishment permitted by this Act;        (2) to provide grants to Qualified Social Equity     Applicants to pay for ordinary and necessary expenses to start and operate a cannabis business establishment permitted by this Act;        (3) to compensate the Department of Commerce and     Economic Opportunity for any costs related to the provision of low-interest loans and grants to Qualified Social Equity Applicants;         (4) to pay for outreach that may be provided or     targeted to attract and support Social Equity Applicants and Qualified Social Equity Applicants;        (5) (blank);         (6) to conduct any study or research concerning the     participation of minorities, women, veterans, or people with disabilities in the cannabis industry, including, without limitation, barriers to such individuals entering the industry as equity owners of cannabis business establishments;        (7) (blank); and        (8) to assist with job training and technical     assistance for residents in Disproportionately Impacted Areas.

Sec. 7-30. Reporting. By January 1, 2021, and on January 1 of every year thereafter, or upon request by the Illinois Cannabis Regulation Oversight Officer, each cannabis business establishment licensed under this Act shall report to the Illinois Cannabis Regulation Oversight Officer, on a form to be provided by the Illinois Cannabis Regulation Oversight Officer, information that will allow it to assess the extent of diversity in the medical and adult use cannabis industry and methods for reducing or eliminating any identified barriers to entry, including access to capital. The information to be collected shall be designed to identify the following:        (1) the number and percentage of licenses provided to     Social Equity Applicants and to businesses owned by minorities, women, veterans, and people with disabilities;        (2) the total number and percentage of employees in     the cannabis industry who meet the criteria in (3)(i) or (3)(ii) in the definition of Social Equity Applicant or who are minorities, women, veterans, or people with disabilities;         (3) the total number and percentage of contractors     and subcontractors in the cannabis industry that meet the definition of a Social Equity Applicant or who are owned by minorities, women, veterans, or people with disabilities, if known to the cannabis business establishment; and        (4) recommendations on reducing or eliminating any     identified barriers to entry, including access to capital, in the cannabis industry.

 Sec. 7-25. Transfer of license awarded to Qualified Social Equity Applicant.     (a) In the event a Qualified Social Equity Applicant seeks to transfer, sell, or grant a cannabis business establishment license within 5 years after it was issued to a person or entity that does not qualify as a Social Equity Applicant, the transfer agreement shall require the new license holder to pay the Cannabis Business Development Fund an amount equal to:         (1) any fees that were waived by any State agency     based on the applicant's status as a Social Equity Applicant, if applicable;        (2) any outstanding amount owed by the Qualified     Social Equity Applicant for a loan through the Cannabis Business Development Fund, if applicable; and        (3) the full amount of any grants that the Qualified     Social Equity Applicant received from the Department of Commerce and Economic Opportunity, if applicable.     (b) Transfers of cannabis business establishment licenses awarded to a Social Equity Applicant are subject to all other provisions of this Act, the Compassionate Use of Medical Cannabis Program Act, and rules regarding transfers. (Source: P.A. 101-27, eff. 6-25-19; 101-593, eff. 12-4-19.)

“Most Japanese people see cannabis as a subculture of Japan but they’re wrong. For thousands of years, cannabis has been at the very heart of Japanese culture,” Japan’s leading expert on cannabis, Takayasu Junichi, told the Asia Pacific Journal in an interview.

C’est sous l’influence des Beatles et des groupes psychédéliques que la mode du cannabis récréatif s’est répandue en Occident à partir du milieu des années 1960. Dans son numéro d’octobre 1971, Mainmise — la publication officielle de la contreculture québécoise — présentait un dossier sur les différents types de hachich (la résine du cannabis).

The Focus Izalco Max has been a big favourite of ours in the past, with its traditional round tubes and straight top tube design making it the main rival to Cannondale’s SuperSix Evo. And, with the Max's frame tipping the scales at a scant 750g (for a 56cm), it was also one of the lightest bikes of its generation.

Contenant immédiat108 Le contenant immédiat dans lequel est emballé un produit du cannabis, à l’exception d’une plante de cannabis ou des graines provenant d’une telle plante, doit satisfaire aux exigences suivantes :a) il est opaque ou translucide;b) il empêche la contamination du cannabis;c) dans le cas du cannabis séché ou d’un accessoire qui en contient, il permet de garder le cannabis au sec;d) il est doté d’un dispositif de sûreté offrant au consommateur une assurance raisonnable qu’il n’a pas été ouvert avant la réception;e) il satisfait aux exigences relatives aux emballages protège-enfants prévues aux paragraphes C.01.001(2) à (4) du Règlement sur les aliments et drogues;f) il contient une quantité de produit n’excédant pas l’équivalent de 30 g de cannabis séché, déterminée selon ce que prévoit le paragraphe 2(4) de la Loi.

There are no audits matching your search

It might be possible, but there is, as yet, no solid evidence to support that belief.

Entrepreneurship of the Cannabis Industry By Jillian Hester